Research programme: antitoxin monoclonal antibodies - Mapp Biopharmaceutical

Drug Profile

Research programme: antitoxin monoclonal antibodies - Mapp Biopharmaceutical

Latest Information Update: 13 Mar 2015

Price : $50

At a glance

  • Originator Mapp Biopharmaceutical
  • Developer Iowa State University; Mapp Biopharmaceutical; Tulane National Primate Research Center; University of California, Davis; Wadsworth Center of New York State Department of Health
  • Class Antitoxins; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections; Ricin poisoning; Staphylococcal infections

Most Recent Events

  • 24 Jan 2015 Preclinical trials in Clostridium infections in USA (Parenteral)
  • 24 Jan 2015 Preclinical trials in Ricin poisoning in USA (Parenteral)
  • 24 Jan 2015 Preclinical trials in Staphylococcal infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top